AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock Price
AGMBStock
$14.02
Market Cap$690.46M
P/E—
PEG Ratio—
Div yield—
Beta1.44
AGMB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-24.04%
Price vs S&P 500 (4W)-0.82%
VGM Score48.66
AGMB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.30
4.30
4.27
4.25
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AGMBAgomAb Therapeutics NV American Depositary Shares | — | — | C | $14.02 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and antibody therapies for chronic fibrotic diseases and related immunological disorders with significant unmet medical needs. The company's pipeline targets established inflammatory pathways using validated modalities, with lead candidates Ontunisertib (AGMB-129) and AGMB-447. AgomAb's approach aims to overcome limitations of existing treatment options for fibrotic indications.